David Lichter Email Address

Executive Director, Clinical Research and Clinical Science and Program Leadership SER-287 and SER-301

Seres Therapeutics, Inc. is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced. A Phase 2 study of Seres' program SER-109 has been completed in multiply recurrent Clostridium difficile infection. Seres' clinical candidate, SER-287, is being evaluated in a Phase 1b study in patients with mild-to-moderate ulcerative colitis (UC). Seres is also developing SER-262, the first ever synthetic microbiome therapeutic candidate, in a Phase 1b study in patients with primary CDI.

Passionate and innovative oncology research scientist and clinical project lead, with extensive background in genetics and molecular cell biology. Award-winning leader in community and student STEM (science, technology, engineering, mathematics) education and CSR (corporate social responsibility).